JPH08506334A - 新規な複素環式アミノメチル‐４ピペリジン誘導体、その調製および治療への使用 - Google Patents

新規な複素環式アミノメチル‐４ピペリジン誘導体、その調製および治療への使用

Info

Publication number: JPH08506334A
Authority: JP; Japan
Prior art keywords: piperidine; ylmethylaminomethyl; benzodioxan; general formula; compound
Prior art date: 1993-02-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP6517735A

Other languages

English (en)

Japanese (ja)

Inventor

ビッグ，ドゥニ

カスタン，フロランス

コーク，ウテール

ボノー，ベルナール

Original Assignee

ピエール、ファーブル、メディカマン

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-11

Filing date

1994-02-10

Publication date

1996-07-09

1994-02-10 Application filed by ピエール、ファーブル、メディカマン filed Critical ピエール、ファーブル、メディカマン

1996-07-09 Publication of JPH08506334A publication Critical patent/JPH08506334A/ja

Status Pending legal-status Critical Current

Links

238000002360 preparation method Methods 0.000 title claims abstract description 6
125000000623 heterocyclic group Chemical group 0.000 title claims abstract description 4
230000001225 therapeutic effect Effects 0.000 title abstract description 5
150000001875 compounds Chemical class 0.000 claims abstract description 40
150000003839 salts Chemical class 0.000 claims abstract description 9
238000000034 method Methods 0.000 claims abstract description 7
-1 1-cyclopropanecarbonyl-4- (1,4-benzodioxan-2-ylmethylaminomethyl) piperidine Chemical compound 0.000 claims description 28
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 24
239000000203 mixture Substances 0.000 claims description 11
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
150000001412 amines Chemical class 0.000 claims description 8
238000006243 chemical reaction Methods 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
208000019901 Anxiety disease Diseases 0.000 claims description 3
208000024172 Cardiovascular disease Diseases 0.000 claims description 3
230000036506 anxiety Effects 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
230000037406 food intake Effects 0.000 claims description 3
235000012631 food intake Nutrition 0.000 claims description 3
230000002496 gastric effect Effects 0.000 claims description 3
238000010606 normalization Methods 0.000 claims description 3
230000028327 secretion Effects 0.000 claims description 3
208000019116 sleep disease Diseases 0.000 claims description 3
230000002792 vascular Effects 0.000 claims description 3
208000019553 vascular disease Diseases 0.000 claims description 3
125000004564 2,3-dihydrobenzofuran-2-yl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 claims description 2
206010020772 Hypertension Diseases 0.000 claims description 2
208000019695 Migraine disease Diseases 0.000 claims description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 2
150000008041 alkali metal carbonates Chemical class 0.000 claims description 2
229910052782 aluminium Inorganic materials 0.000 claims description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
208000026106 cerebrovascular disease Diseases 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
230000002526 effect on cardiovascular system Effects 0.000 claims description 2
239000012442 inert solvent Substances 0.000 claims description 2
150000007529 inorganic bases Chemical class 0.000 claims description 2
239000012280 lithium aluminium hydride Substances 0.000 claims description 2
206010027599 migraine Diseases 0.000 claims description 2
150000007522 mineralic acids Chemical class 0.000 claims description 2
125000002950 monocyclic group Chemical group 0.000 claims description 2
150000007524 organic acids Chemical class 0.000 claims description 2
235000005985 organic acids Nutrition 0.000 claims description 2
150000007530 organic bases Chemical class 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
125000003367 polycyclic group Chemical group 0.000 claims description 2
238000010992 reflux Methods 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
125000004434 sulfur atom Chemical group 0.000 claims description 2
150000003512 tertiary amines Chemical class 0.000 claims description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
239000008096 xylene Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 2
BQTGIWZEECMTNH-UHFFFAOYSA-N 1-[1-(1-adamantylmethyl)piperidin-4-yl]-n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)methanamine Chemical compound C1C(C2)CC(C3)CC2CC13CN(CC1)CCC1CNCC1OC2=CC=CC=C2OC1 BQTGIWZEECMTNH-UHFFFAOYSA-N 0.000 claims 1
BRUQIMLXZBKDST-UHFFFAOYSA-N cyclobutyl-[4-[(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)methyl]piperidin-1-yl]methanone Chemical compound C1CC(CNCC2OC3=CC=CC=C3OC2)CCN1C(=O)C1CCC1 BRUQIMLXZBKDST-UHFFFAOYSA-N 0.000 claims 1
WMPAYLFFXCTRDW-UHFFFAOYSA-N cycloheptyl-[4-[(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)methyl]piperidin-1-yl]methanone Chemical compound C1CC(CNCC2OC3=CC=CC=C3OC2)CCN1C(=O)C1CCCCCC1 WMPAYLFFXCTRDW-UHFFFAOYSA-N 0.000 claims 1
QXEGUDXRSQVKBQ-UHFFFAOYSA-N cyclohexyl-[4-[(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)methyl]piperidin-1-yl]methanone Chemical compound C1CC(CNCC2OC3=CC=CC=C3OC2)CCN1C(=O)C1CCCCC1 QXEGUDXRSQVKBQ-UHFFFAOYSA-N 0.000 claims 1
ANPWFHUHQDCEKV-UHFFFAOYSA-N cyclopentyl-[4-[(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)methyl]piperidin-1-yl]methanone Chemical compound C1CC(CNCC2OC3=CC=CC=C3OC2)CCN1C(=O)C1CCCC1 ANPWFHUHQDCEKV-UHFFFAOYSA-N 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
125000003118 aryl group Chemical group 0.000 description 15
239000000047 product Substances 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 11
238000002474 experimental method Methods 0.000 description 10
239000012074 organic phase Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000000921 elemental analysis Methods 0.000 description 7
238000005160 1H NMR spectroscopy Methods 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
238000001035 drying Methods 0.000 description 6
239000003480 eluent Substances 0.000 description 6
238000001914 filtration Methods 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000005406 washing Methods 0.000 description 6
239000007795 chemical reaction product Substances 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
230000000862 serotonergic effect Effects 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000006073 displacement reaction Methods 0.000 description 3
235000019439 ethyl acetate Nutrition 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
239000001530 fumaric acid Substances 0.000 description 3
239000011535 reaction buffer Substances 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
SAISBVKHILBXRE-UHFFFAOYSA-N 1-[1-(2-cyclohexylethyl)piperidin-4-yl]-N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)methanamine Chemical compound C1CCC(CC1)CCN2CCC(CC2)CNCC3COC4=CC=CC=C4O3 SAISBVKHILBXRE-UHFFFAOYSA-N 0.000 description 2
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001270 agonistic effect Effects 0.000 description 2
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
230000027455 binding Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 2
229960002495 buspirone Drugs 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229940126543 compound 14 Drugs 0.000 description 2
229940125810 compound 20 Drugs 0.000 description 2
229940125961 compound 24 Drugs 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
VNJOEUSYAMPBAK-UHFFFAOYSA-N 2-methylbenzenesulfonic acid;hydrate Chemical compound O.CC1=CC=CC=C1S(O)(=O)=O VNJOEUSYAMPBAK-UHFFFAOYSA-N 0.000 description 1
241000819038 Chichester Species 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000007799 cork Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000003194 forelimb Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
229960001779 pargyline Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

JP6517735A 1993-02-11 1994-02-10 新規な複素環式アミノメチル‐４ピペリジン誘導体、その調製および治療への使用 Pending JPH08506334A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR93/01525		1993-02-11
FR9301525A FR2701479B1 (fr)	1993-02-11	1993-02-11	Nouveaux dérivés hétérocycliques de l'aminométhyl-4 pipéridine, leur préparation et leur application en thérapeutique.
PCT/FR1994/000152 WO1994018193A1 (fr)	1993-02-11	1994-02-10	Nouveaux derives heterocycliques de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
JPH08506334A true JPH08506334A (ja)	1996-07-09

Family

ID=9443949

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP6517735A Pending JPH08506334A (ja)	1993-02-11	1994-02-10	新規な複素環式アミノメチル‐４ピペリジン誘導体、その調製および治療への使用

Country Status (8)

Country	Link
EP (1)	EP0683775A1 (fr)
JP (1)	JPH08506334A (fr)
AU (1)	AU6003394A (fr)
CA (1)	CA2155849A1 (fr)
FR (1)	FR2701479B1 (fr)
NZ (1)	NZ261331A (fr)
WO (1)	WO1994018193A1 (fr)
ZA (1)	ZA94910B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2725989B1 (fr) *	1994-10-20	1997-01-10	Pf Medicament	Nouvelles 2-(1-(omega-phenoxyalcoylpiperidin-4-yl) aminomethylene)-2h-benzofuran-3-ones substituees, leur preparation et leur application en therapeutique
GB9627006D0 (en) *	1996-12-27	1997-02-12	Knoll Ag	Therapeutic agents
US7189753B1 (en)	1997-11-06	2007-03-13	Cady Roger K	Preemptive prophylaxis of migraine
GB9811879D0 (en) *	1998-06-03	1998-07-29	Knoll Ag	Therapeutic agents
DE10120619A1 (de) *	2001-04-26	2002-10-31	Merck Patent Gmbh	2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman
US7435837B2 (en)	2003-10-24	2008-10-14	Wyeth	Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en)	2003-10-24	2010-06-01	Wyeth Llc	Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
WO2008052078A2 (fr) *	2006-10-24	2008-05-02	Wyeth	Dérivés de benzoxathine et de benzoxathiole, et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4910302A (en) *	1988-12-19	1990-03-20	American Home Products Corporation	Psychotropic polycyclic imides
FR2658823B1 (fr) *	1990-02-27	1992-04-30	Adir	Nouveaux derives d'aminomethylpiperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent .
FR2659323B1 (fr) *	1990-03-07	1992-06-12	Synthelabo	Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.
FR2660657B1 (fr) *	1990-04-09	1993-05-07	Adir	Nouveaux derives du 3-aminochromane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

1993
- 1993-02-11 FR FR9301525A patent/FR2701479B1/fr not_active Expired - Fee Related
1994
- 1994-02-10 NZ NZ261331A patent/NZ261331A/en unknown
- 1994-02-10 CA CA002155849A patent/CA2155849A1/fr not_active Abandoned
- 1994-02-10 WO PCT/FR1994/000152 patent/WO1994018193A1/fr not_active Ceased
- 1994-02-10 AU AU60033/94A patent/AU6003394A/en not_active Abandoned
- 1994-02-10 JP JP6517735A patent/JPH08506334A/ja active Pending
- 1994-02-10 ZA ZA94910A patent/ZA94910B/xx unknown
- 1994-02-10 EP EP94906261A patent/EP0683775A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
WO1994018193A1 (fr)	1994-08-18
AU6003394A (en)	1994-08-29
ZA94910B (en)	1994-08-22
FR2701479B1 (fr)	1995-05-12
NZ261331A (en)	1996-05-28
CA2155849A1 (fr)	1994-08-18
FR2701479A1 (fr)	1994-08-19
EP0683775A1 (fr)	1995-11-29

Publication	Publication Date	Title
DE69503803T2 (de)	1999-04-15	3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament
US5591743A (en)	1997-01-07	3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives as 5HT1A ligands
US6143769A (en)	2000-11-07	Phenylacetic acid benzylamides
AU683460B2 (en)	1997-11-13	Propenoic acid derivatives
US5143916A (en)	1992-09-01	Naphthylpiperazines useful as 5-ht1a receptor ligands
JPH10500989A (ja)	1998-01-27	５ｈｔ１ａ拮抗薬としてのピペラジン誘導体
DK159146B (da)	1990-09-10	Analogifremgangsmaade til fremstilling af 1,2-diaminocyclobuten-3,4-dioner og cyclobuten-3,4-dionderivater til anvendelse som mellemprodukter i fremgangsmaaden
WO2016165650A1 (fr)	2016-10-20	Cocristal d'olaparib et d'urée et son procédé de préparation
EP2807147A1 (fr)	2014-12-03	Dérivés de phényle méthanesulfonamide utilisés comme inhibiteurs mgat - 2
JP2927480B2 (ja)	1999-07-28	ピペリジン系化合物、その製造方法及びこれを含有する医薬組成物
JPH05507081A (ja)	1993-10-14	新規のスルホニル化合物
JP2002500663A (ja)	2002-01-08	新規な経口用で活性な鉄（ｉｉｉ）キレート化剤
TW438746B (en)	2001-06-07	New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions
JPH01502757A (ja)	1989-09-21	向精神薬二環イミド類
JP5852269B2 (ja)	2016-02-03	Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体
IE910747A1 (en)	1991-09-11	Derivatives of 4-(aminomethyl)-piperidine, their preparation¹and their therapeutic application
NO178968B (no)	1996-04-01	Analogifremgangsmåte for fremstilling av terapeutisk aktive aminopyrimidin-karboksamidderivater
JPH08506334A (ja)	1996-07-09	新規な複素環式アミノメチル‐４ピペリジン誘導体、その調製および治療への使用
JPH05509311A (ja)	1993-12-22	１，４―二置換ピペラジン
JP2022526827A (ja)	2022-05-26	（ｅ）－３－［２－（２－チエニル）ビニル］－１ｈ－ピラゾールの固体形態
US5166156A (en)	1992-11-24	Naphthyl piperazines useful as 5-HT1A receptor ligands
SK281387B6 (sk)	2001-03-12	Deriváty kyseliny hydroxímovej, farmaceutický prostriedok, ktorý ich obsahuje, spôsob ich prípravy a medziprodukty na ich prípravu
JPH08507302A (ja)	1996-08-06	新規な２−フェノキシエチルアミン誘導体、その調製およびその治療への使用
US5166157A (en)	1992-11-24	Naphthyl piperazines useful as 5-HT1A receptor ligands
JPH05201978A (ja)	1993-08-10	Ｎ−（４，７−ジメトキシ−２−インダニル）−１−（フェニルカルボニル）−ｎ−プロピル−４−ピペリジンメタンアミン誘導体、その製造法および医薬への応用

JPH08506334A - 新規な複素環式アミノメチル‐４ ピペリジン誘導体、その調製および治療への使用 - Google Patents